Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, gives his perspective on the data submitted to BSH 2020 on the UKMRA OPTIMUM (MUK Nine) which looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).